Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis

Histopathology

Volumn 61, Issue 2, 2012, Pages 283-292

  Mohammed, Zahra M A ^a,b   Edwards, Joanne ^a   Orange, Clare ^b   Mallon, Elizabeth ^b   Doughty, Julie C ^c   Mcmillan, Donald C ^a   Going, James J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

Automated weighted histoscore assessment; Observer weighted histoscore assessment; Primary invasive breast cancer; Survival

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84864384785     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04244.x     Document Type: Article

References (19)

1. Lal P, Tan LK, Chen B. Correlation of her-2 status with estrogen and progesterone receptors and histologic features in 3, 655 invasive breast carcinomas. Am. J. Clin. Pathol. 2005; 123; 541-546.
2. Schnitt SJ. Traditional and newer pathologic factors. J. Natl Cancer Inst. Monogr. 2001; 30; 22-26.
3. Diaz LK, Sahin A, Sneige N. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Ann. Diagn. Pathol. 2004; 8; 23-27.
4. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999; 17; 1474-1481.
5. Layfield LJ, Gupta D, Mooney EE. Assessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques, and quantitation methods. Breast J. 2000; 6; 189-196.
6. Adams EJ, Green JA, Clark AH et al. Comparison of different scoring systems for immunohistochemical staining. J. Clin. Pathol. 1999; 52; 75-77.
7. van Diest PJ, Weger DR, Lindholm J. Reproducibility of subjective immunoscoring of steroid receptors in breast cancer. Anal. Quant. Cytol. Histol. 1996; 18; 351-354.
8. Faratian D, Kay C, Robson T et al. Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the team trial experience. Histopathology 2009; 55; 587-593.
9. Bolton KL, Garcia-Closas M, Pfeiffer RM et al. Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol. Biomarkers Prev. 2010; 19; 992-999.
10. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998; 4; 844-847.
11. Tovey SM, Witton CJ, Bartlett JMS et al. Outcome and human epidermal growth factor receptor (her) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004; 6; R246-R251.
12. Allred DC, Harvey JM, Berardo M et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998; 11; 155-168.
13. McCarty KSJ, Szabo E, Flowers JL et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986; 46; 4244s-4248s.
14. Kirkegaard T, Edwards J, Tovey S et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006; 48; 787-794.
15. Kurosumi M. Immunohistochemical assessment of hormone receptor status using a new scoring system (j-score) in breast cancer. Breast Cancer 2007; 14; 189-193.
16. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33; 159-174.
17. Gokhale S, Rosen D, Sneige N et al. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 2007; 15; 451-455.
18. Rexhepaj E, Brennan DJ, Holloway P et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res. 2008; 10; R89.
19. Turbin DA, Leung S, Cheang MCU et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3, 484 cases. Breast Cancer Res. Treat. 2008; 110; 417-426.